Surgical robots: who is gaining ground, who is defending it, and why it matters to you

The read in plain words

Surgical and medical robotics is a competition story right now. Most of the newest facts on these companies are about who is taking ground and who is defending it. The pattern is consistent: the strongest positions rest on revenue that keeps coming in after a system is placed, and the challengers attack from the edges, with new system generations, adjacent procedures and regional rivals.

Two facts carry the read. Intuitive Surgical said 84% of its revenue was recurring in Q3 FY2026.³ An industry research note from the same week says Intuitive faces competition from companies offering alternative surgical approaches or robotic-assisted surgical systems, including domestic competitors in markets such as China.⁵ One fact describes the moat. The other describes the pressure on it.

For an investor, the useful question is where each company makes its stand and whether the facts show that stand holding, not who has the flashiest robot. The rest of this piece goes company by company.

Intuitive Surgical: the incumbent with a recurring base

$ISRG ranks first in our data, and its defensive position is easy to see. Recurring revenue means sales that repeat once a system is in use, as opposed to a one-time sale of the machine. At 84% of the total in Q3 FY2026, nearly all of Intuitive's revenue comes from that base.³

That matters in a competitive market because a rival has to do more than match the robot. A hospital already running procedures on an installed system has workflows, trained staff and a steady flow of activity built around it. A challenger has to make the case for changing all of that, not just for a better machine.

Management frames the opportunity as large. On its Q2 FY2026 call, Intuitive said it believes there is a substantial and durable opportunity to fundamentally improve surgery and acute interventions with its technology.⁶ That is the company's view, and how it plays out depends on adoption. But the reference to acute interventions points beyond the procedures the market usually links to the company.

The pressure point is explicit. The research note names competitors with alternative approaches and other robotic systems, and singles out domestic competitors in certain regions such as China.⁵ Our view: the recurring base protects Intuitive where its systems are already placed. The open contest is in markets where local rivals can compete before that base is built.

Stryker: breadth as the competitive weapon

Stryker ranks third in our data and competes by covering a lot of ground. Its Mako robotic system is installed across 47 countries and has performed over 2.5 million procedures globally, according to the company's Q2 FY2026 call.² An installed footprint that wide is its own form of the recurring logic described above: each placed system anchors future procedures.

Stryker is also contesting a different arena. On the same call, the company said it competes in the mechanical thrombectomy market with a full suite of products, including a clot retriever and a flow retriever.⁷ Mechanical thrombectomy means removing a blood clot with a device rather than with drugs alone, so this is vascular work, not orthopedics.

Strategically, a full suite is how a company tries to win share in a crowded device category. It lets Stryker offer a hospital several tools rather than one. How to think about it: Stryker's edge in the facts is reach, both across geographies with Mako and across product categories with thrombectomy.^2,7 The test is whether that reach turns into share gains the company reports in later quarters.

Zimmer Biomet: winning on the product mix inside a category

Zimmer Biomet ranks second in our data. Its competitive facts show a company gaining ground inside an existing category rather than opening a new one. Its Hips segment grew 5.1% on a constant currency basis in Q2 2026.⁴ Constant currency removes exchange-rate swings, so the figure reflects underlying business growth.

The more telling detail is pricing. Zimmer Biomet said it receives a 40% premium when hospitals convert from non-iodine-coated to iodine-coated hip devices.⁸ When a product earns that kind of premium over the version it replaces, it suggests customers see a real difference. In a competitive market, that difference is what protects share without having to cut price.

Management also called its people and culture a growing competitive advantage.⁹ That is softer evidence than a pricing figure. Still, it is how the company explains its own execution, and it is worth checking against results over time.

Our view: Zimmer Biomet's case in the facts is about upgrading the mix. Each conversion to a premium device improves the economics of a procedure the company already serves.⁸ Whether more of its base converts is the thing to track.

PROCEPT BioRobotics: when an upgrade cycle becomes a share story

PROCEPT BioRobotics shows the challenger side of the market. On its Q2 FY2026 call, the company said HYDROS is replacing AQUABEAM systems, which it described as indicating a shift in market share.¹

The lesson carries across the group. In surgical robotics, a new system generation is more than a product launch. It is a chance to reset the installed base, and the installed base is where recurring activity lives. A company that gets its customers onto a new platform keeps them, and a company that does it well can take ground at the same time.

That links back to the main read. Intuitive's recurring share, Stryker's Mako footprint and PROCEPT's replacement cycle are three versions of the same competitive logic: own the system, and the procedures follow.^3,2,1

What to watch next

The facts point to a few clear signposts. For Intuitive, watch whether recurring revenue stays this dominant in the mix and whether the company says anything new about competition in China and other regions where domestic rivals operate.^3,5 Those two together show whether the moat is holding where it is being tested.

For Stryker, the signal is whether its full thrombectomy suite and its Mako footprint show up as reported share gains.^7,2 For Zimmer Biomet, watch whether hip growth holds and how far the shift to iodine-coated devices goes.^4,8 For PROCEPT, the question is how much of the AQUABEAM base moves to HYDROS.¹

In our view the clearest way to read this market is to follow installed systems and the upgrades that keep them current. That is where these companies say they are competing, and where the next set of results will show who is gaining.